^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HRS-4642

    i
    Other names: HRS-4642, HRS 4642, HRS4642, SHR-4642
    Associations

    News

    Trials
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    KRAS G12D inhibitor
    Related drugs:
    Associations

    News

    Trials
    29d
    A Phase III Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    gemcitabine • albumin-bound paclitaxel • HRS-4642
    1m
    HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation (clinicaltrials.gov)
    P2, N=40, Recruiting, Zhejiang University | Not yet recruiting --> Recruiting | Initiation date: Nov 2025 --> Feb 2026
    Enrollment open • Trial initiation date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    paclitaxel • TheraCIM (nimotuzumab) • HRS-4642
    2ms
    HRS-4642 combined with Nimotuzumab in the treatment of recurrent or metastatic pancreatic ductal adenocarcinoma with KRAS G12D mutation that has failed systemic therapy (ChiCTR2500098420)
    P1/2, N=20, Recruiting, West China Hospital,Sichuan University; West China Hospital,Sichuan University | N=10 --> 20
    Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase) • CA 19-9 (Cancer antigen 19-9)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    TheraCIM (nimotuzumab) • HRS-4642
    2ms
    HRS-4642-206: Phase IB/II clinical study of the safety, tolerability and efficacy of HRS-4642 in combination with other anti-tumor drugs in subjects with solid tumors (ChiCTR2500115250)
    P1/2, N=60, Not yet recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital
    New P1/2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    AiRuiLi (adebrelimab) • HRS-4642
    2ms
    HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • albumin-bound paclitaxel • AiRuiLi (adebrelimab) • HRS-4642
    3ms
    Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer (clinicaltrials.gov)
    P2, N=160, Recruiting, Fudan University | Not yet recruiting --> Recruiting | N=120 --> 160
    Enrollment open • Enrollment change
    |
    trastuzumab rezetecan (SHR-A1811) • SHR-A2102 • AiRuiLi (adebrelimab) • HRS-4642 • garetatug rezetecan (SHR-A1904)
    3ms
    HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • albumin-bound paclitaxel • AiRuiLi (adebrelimab) • HRS-4642
    3ms
    HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors (clinicaltrials.gov)
    P1/2, N=60, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P1/2 trial
    |
    gemcitabine • albumin-bound paclitaxel • AiRuiLi (adebrelimab) • HRS-4642
    4ms
    HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Zhejiang University
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    paclitaxel • TheraCIM (nimotuzumab) • HRS-4642
    4ms
    HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P3, N=588, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P3 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    HRS-4642
    4ms
    HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=20, Recruiting, West China Hospital | N=10 --> 20
    Enrollment change
    |
    TheraCIM (nimotuzumab) • HRS-4642
    6ms
    HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients (clinicaltrials.gov)
    P2, N=32, Recruiting, Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    gemcitabine • albumin-bound paclitaxel • TheraCIM (nimotuzumab) • HRS-4642